Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 1
1983 6
1984 3
1985 1
1986 6
1987 15
1988 14
1989 11
1990 14
1991 22
1992 11
1993 14
1994 9
1995 9
1996 8
1997 16
1998 14
1999 6
2000 6
2001 13
2002 6
2003 8
2004 6
2005 15
2006 12
2007 8
2008 9
2009 5
2010 8
2011 6
2012 6
2013 4
2014 9
2015 4
2016 7
2017 7
2018 6
2019 8
2020 5
2021 6
2022 5
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

339 results

Results by year

Filters applied: . Clear all
Page 1
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 …
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurre …
Nilutamide.
[No authors listed] [No authors listed] 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Mar 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643487 Free Books & Documents. Review.
Nilutamide is a first generation, oral nonsteroidal antiandrogen similar in structure to flutamide that is used in the therapy of prostate cancer. Nilutamide is associated with a low rate of serum aminotransferase elevations during therapy and with rare instances of …
Nilutamide is a first generation, oral nonsteroidal antiandrogen similar in structure to flutamide that is used in the therapy of pro …
Design of antiandrogens and their mechanisms of action: a case study (anandron).
Raynaud JP, Fiet J, Le Goff JM, Martin PM, Moguilewsky M, Ojasoo T. Raynaud JP, et al. Horm Res. 1987;28(2-4):230-41. doi: 10.1159/000180948. Horm Res. 1987. PMID: 3331376 Review.
The present paper describes the results of our assays of plasma 3 alpha-androstanediol glucuronide, 5 alpha-reductase and androgen receptor in prostate cancer patients. The activity of the nonsteroid antiandrogen anandron is discussed in relation to these parameters: an …
The present paper describes the results of our assays of plasma 3 alpha-androstanediol glucuronide, 5 alpha-reductase and androgen receptor …
Antiandrogens.
[No authors listed] [No authors listed] 2014 Jun 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2014 Jun 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643810 Free Books & Documents. Review.
In contrast, flutamide, nilutamide and bicalutamide are now approved and in general clinical use for therapy of prostate cancer. ...Unlike flutamide, nilutamide has not been evaluated in detail as therapy of hirsutism or acne. ...
In contrast, flutamide, nilutamide and bicalutamide are now approved and in general clinical use for therapy of prostate cancer. ...U …
The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
Raynaud JP, Bonne C, Moguilewsky M, Lefebvre FA, Bélanger A, Labrie F. Raynaud JP, et al. Prostate. 1984;5(3):299-311. doi: 10.1002/pros.2990050307. Prostate. 1984. PMID: 6374639 Review.
The nonsteroidal antiandrogen RU 23908 ( Anandron ) weakly interacts with the prostatic cytosolic androgen receptor and shows a fast dissociation rate. ...
The nonsteroidal antiandrogen RU 23908 ( Anandron ) weakly interacts with the prostatic cytosolic androgen receptor and shows a fast …
Pharmacological and clinical studies of the antiandrogen Anandron.
Moguilewsky M, Bertagna C, Hucher M. Moguilewsky M, et al. J Steroid Biochem. 1987;27(4-6):871-5. doi: 10.1016/0022-4731(87)90162-2. J Steroid Biochem. 1987. PMID: 3320565 Review.
This paper summarizes the animal and human studies with Anandron available at the time of the meeting. The following was demonstrated in the rat and confirmed in man: interaction of Anandron with the prostatic androgen receptor, antiandrogen activity against testost …
This paper summarizes the animal and human studies with Anandron available at the time of the meeting. The following was demonstrated …
Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate.
Pendyala L, Creaven PJ, Huben R, Tremblay D, Bertagna C. Pendyala L, et al. Cancer Chemother Pharmacol. 1988;22(1):69-76. doi: 10.1007/BF00254185. Cancer Chemother Pharmacol. 1988. PMID: 3396147
The pharmacokinetics of total radioactivity and unchanged drug were studied in patients receiving Anandron (Nilutamide, RU 23908) after a single dose of [14C] Anandron and after q12 h dosings of unlabelled drug for 2-7 weeks. ...Urinary excretion of radioacti …
The pharmacokinetics of total radioactivity and unchanged drug were studied in patients receiving Anandron (Nilutamide, RU 239 …
The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
Moguilewsky M, Tournemine C. Moguilewsky M, et al. Am J Clin Oncol. 1988;11 Suppl 2:S148-51. doi: 10.1097/00000421-198801102-00035. Am J Clin Oncol. 1988. PMID: 3149454
This could be explained (a) by an additivity of effects: inhibition by Anandron of the action of residual testosterone unsuppressed by buserelin on the prostate and prevention by buserelin of the rebound testosterone increase induced by Anandron: (b) by a potentiati …
This could be explained (a) by an additivity of effects: inhibition by Anandron of the action of residual testosterone unsuppressed b …
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Moguilewsky M, Fiet J, Tournemine C, Raynaud JP. Moguilewsky M, et al. J Steroid Biochem. 1986 Jan;24(1):139-46. doi: 10.1016/0022-4731(86)90043-9. J Steroid Biochem. 1986. PMID: 3009970
Among antiandrogens acting through the androgen receptor (AR), the nonsteroid anandron (RU 23908) has several advantages over available compounds: megestrol acetate and cyproterone acetate, both steroids, bind substantially to other hormone receptors (progestin, gluco- and …
Among antiandrogens acting through the androgen receptor (AR), the nonsteroid anandron (RU 23908) has several advantages over availab …
Antiandrogenic drugs.
McLeod DG. McLeod DG. Cancer. 1993 Feb 1;71(3 Suppl):1046-9. doi: 10.1002/1097-0142(19930201)71:3+<1046::aid-cncr2820711424>3.0.co;2-m. Cancer. 1993. PMID: 8428326 Review.
Nonsteroidal antiandrogenic agents (flutamide, Casodex [ICI Pharmaceuticals, England], and nilutamide) block cellular binding of androgens only, and there is no reduction of testosterone levels. ...
Nonsteroidal antiandrogenic agents (flutamide, Casodex [ICI Pharmaceuticals, England], and nilutamide) block cellular binding of andr …
339 results